• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MILTENYI BIOTEC CLINIMACS; CLINIMACS SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MILTENYI BIOTEC CLINIMACS; CLINIMACS SYSTEM Back to Search Results
Model Number CLINIMACS PLUS INSTRUMENT
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Abdominal Pain (1685); Death (1802); Disseminated Intravascular Coagulation (DIC) (1813); Bone Fracture(s) (1870); Hemorrhage/Bleeding (1888); Low Blood Pressure/ Hypotension (1914); Unspecified Infection (1930); Renal Failure (2041); Tachycardia (2095); Toxicity (2333); Respiratory Failure (2484); Osteopenia/ Osteoporosis (2651)
Event Date 09/19/2014
Event Type  Death  
Event Description
(b)(6) is a (b)(6) boy who was diagnosed as having severe combine immune deficiency on newborn screening.He underwent an unrelated bone marrow transplant on (b)(6) 2014.His course has been complicated by toxicity and infection.He was admitted to the picu on three separate occasions; firstly on (b)(6) 2014 for fluid overload and was transferred back to the bmtu on (b)(6) 2014; secondly on (b)(6) 2014 for severe vod and returned to bmtu on (b)(6) 2014; and lastly on (b)(6) 2014 and stayed until the time of his death.His infectious complications were: disseminated cmv pre and post transplant; disseminated ebv post-transplant; pulmonary aspergillosis; pjp pneumonia (based on clinical symptoms); presumed sepsis culture negative (abdominal pain, tachycardia, hypotension).His toxicities were respiratory failure; severe vod; pulmonary hemorrhage; osteopenia with multiple small bone fractures; pancreatitis; renal insufficiency requiring peritoneal dialysis; ards; hypertriglyceridemia.All medically appropriate intensive care was provided in order to sustain him.However, it had become more difficult to maintain his oxygenation despite the use of oscillator ventilator and nitric oxide.On (b)(6) 2014 he was made and (allowed natural death) by his parents and the picu attending at 0200 and he succumbed at 0955.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CLINIMACS
Type of Device
CLINIMACS SYSTEM
Manufacturer (Section D)
MILTENYI BIOTEC
bergisch gladbach
D5142 9
MDR Report Key4119133
MDR Text Key4922852
Report NumberMW5038339
Device Sequence Number1
Product Code KSR
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Nurse
Type of Report Initial
Report Date 09/22/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/22/2014
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date08/01/2015
Device Model NumberCLINIMACS PLUS INSTRUMENT
Device Catalogue Number171-01/70025/16201
Device Lot Number6131007010/D0481/B2010
Is the Reporter a Health Professional? Yes
Is This a Reprocessed and Reused Single-Use Device? Yes
Patient Sequence Number1
Treatment
SULFAMETHOXAZOLE-TRIMETHOPRIM 45 MG IV Q 6 HOURS; URSODIOL 75 MG BID; CHOLECALCIFEROL 1000 UNITS Q DAY; RITUXIMAB 150 MG IV Q 7 DAYS X 4 DOSES; MEROPENEM 400 MG IV Q 8 HOURS; CHLOROTHIAZIDE 8 MG IV Q 12 HOURS; EPOTIN ALFA 3500 UNITS Q M-W-F IV; GANCICLOVIR 50 MG IV Q 12 HOURS; CLONIDINE 0.2 MG TRANSDERMAL PATCH; VORICONAZOLE 150 MG IV Q 12 HOURS; VANCOMYCIN 150 MG IV Q 18 HOURS; AMPHOTERICIN B LIPOSOMAL 50 MG VI Q DAY; METHYLPREDNISOLONE 5 MG Q 6 HOURS; MICAFUNGIN 50 MG IV Q DAY; IMMUNE GLOBULIN INFUSION IV 3 GRAMS; LORAZEPAM 0.25 MG Q 8 HOURS
Patient Outcome(s) Death;
Patient Age10 MO
Patient Weight11
-
-